What question did this study set out to answer?

To engineer and evaluate the preclinical antitumor efficacy and safety profile of a bispecific T-cell engager targeting the leader sequence-derived cathepsin G peptide CG1 presented by HLA-A2.

February 12, 2025LeukemiaOpen Access

Immunotherapy targeting a leader sequence cathepsin G-derived peptide

View Full Paper

Ask AI

Bookmark

Authors

CSChunhua Shi ZTZe Tian JYJun Yan

Discussion

Member takes

Overview

Preclinical study demonstrates selective leukemic cytotoxicity by a novel bispecific T-cell engager in acute myeloid leukemia, supporting its clinical progression.

Key Points

To engineer and evaluate the preclinical antitumor efficacy and safety profile of a bispecific T-cell engager targeting the leader sequence-derived cathepsin G peptide CG1 presented by HLA-A2.
Engineered a T-cell receptor-mimic bispecific antibody (CG1/A2xCD3) designed to bind the CG1/HLA-A2 complex and CD3.
Evaluated binding affinity, T-cell activation, and cytotoxic efficacy against HLA-A2+ acute myeloid leukemia cell lines and primary patient blasts in vitro and in vivo.
Assessed off-target cytotoxic activity using healthy human bone marrow samples.
CG1/A2xCD3 demonstrated high binding affinity to CG1/HLA-A2 complexes and stimulated potent cytotoxic killing of HLA-A2+ primary leukemia blasts and cell lines both in vitro and in vivo.
Tumor cell destruction correlated with target-dependent T-cell activation and robust cytokine secretion.
The bispecific antibody exhibited no cytotoxic activity against normal bone marrow cells.

Cite This Study

Shi et al. (2025) studied this question.

synapsesocial.com/papers/6a105d62d478ddac0ffcc7db https://doi.org/10.1038/s41375-025-02520-x

View Full Paper

Ask AI

Bookmark

February 12, 2025LeukemiaOpen Access

Immunotherapy targeting a leader sequence cathepsin G-derived peptide

View Full Paper

Ask AI

Bookmark

Authors

CSChunhua Shi ZTZe Tian JYJun Yan

Discussion

Member takes

Overview

Preclinical study demonstrates selective leukemic cytotoxicity by a novel bispecific T-cell engager in acute myeloid leukemia, supporting its clinical progression.

Key Points

To engineer and evaluate the preclinical antitumor efficacy and safety profile of a bispecific T-cell engager targeting the leader sequence-derived cathepsin G peptide CG1 presented by HLA-A2.
Engineered a T-cell receptor-mimic bispecific antibody (CG1/A2xCD3) designed to bind the CG1/HLA-A2 complex and CD3.
Evaluated binding affinity, T-cell activation, and cytotoxic efficacy against HLA-A2+ acute myeloid leukemia cell lines and primary patient blasts in vitro and in vivo.
Assessed off-target cytotoxic activity using healthy human bone marrow samples.
CG1/A2xCD3 demonstrated high binding affinity to CG1/HLA-A2 complexes and stimulated potent cytotoxic killing of HLA-A2+ primary leukemia blasts and cell lines both in vitro and in vivo.
Tumor cell destruction correlated with target-dependent T-cell activation and robust cytokine secretion.
The bispecific antibody exhibited no cytotoxic activity against normal bone marrow cells.

Cite This Study

Shi et al. (2025) studied this question.

synapsesocial.com/papers/6a105d62d478ddac0ffcc7db https://doi.org/10.1038/s41375-025-02520-x

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark